Derek Littlejohn
Psychiatric/Mental Health · Indianapolis, INNPI 1912676669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,253 and has fallen 69.7% since, to $683 in 2025. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$1K
- AbbVie$941
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$460
- Ironshore Pharmaceuticals Inc.$375
- Johnson & Johnson$360
- Otsuka America Pharmaceutical, Inc.$286
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,953100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 72 | $1,015 |
| AbbVie | 44 | $941 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $460 |
| Ironshore Pharmaceuticals Inc. | 32 | $375 |
| Johnson & Johnson | 22 | $360 |
| Otsuka America Pharmaceutical, Inc. | 15 | $286 |
| Axsome Therapeutics, Inc. | 12 | $233 |
| Tris Pharma Inc | 6 | $143 |
| Noven Therapeutics, LLC | 7 | $128 |
| Bausch Health US, LLC | 7 | $124 |
| Vanda Pharmaceuticals Inc. | 4 | $112 |
| Corium, LLC | 9 | $104 |
| Neos Therapeutics, LP | 6 | $104 |
| Alkermes, Inc. | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Indivior Inc. | 3 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Lundbeck LLC | 3 | $45 |
| Merck | 3 | $42 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Neuronetics, Inc. | 1 | $30 |
| Braeburn Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,953 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 24 | $320 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Indianapolis
- Sonya RuedlingerIndianapolis$134K
- Devan GravesIndianapolis$12K
- Clyde YanIndianapolis$9K
- Beth DelamboIndianapolis$7K
- Olga Marie JiodioIndianapolis$6K
- Lindsay RussellIndianapolis$5K
- Nina VoigtIndianapolis$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.